Identification of a large intra-exonic deletion in

BRCA2 deletion pancreatic cancer rearrangement variant of unknown significance

Journal

Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808

Informations de publication

Date de publication:
2023
Historique:
received: 01 07 2022
accepted: 30 11 2022
entrez: 26 1 2023
pubmed: 27 1 2023
medline: 27 1 2023
Statut: epublish

Résumé

By 2030, pancreatic cancer will become the second leading cause of cancer-related deaths in the United States and in Europe. The management of patients with advanced pancreatic cancer relies on chemotherapy and poly (ADP-ribose) polymerase inhibitors for patients who carry

Identifiants

pubmed: 36700131
doi: 10.1177/17588359221146132
pii: 10.1177_17588359221146132
pmc: PMC9869184
doi:

Types de publication

Case Reports

Langues

eng

Pagination

17588359221146132

Informations de copyright

© The Author(s), 2023.

Déclaration de conflit d'intérêts

PH has participated in the POLO trial and is a consultant for AstraZeneca and BMS. The remaining authors declare no conflict of interest.

Références

World J Gastroenterol. 2014 Aug 21;20(31):10778-89
pubmed: 25152581
J Med Genet. 2016 Aug;53(8):548-58
pubmed: 27060066
Cell Cycle. 2015;14(21):3389-95
pubmed: 26566862
Eur J Hum Genet. 2017 Oct;25(10):1147-1154
pubmed: 28905878
Lab Invest. 2021 Aug;101(8):1048-1059
pubmed: 34031538
Sci Rep. 2018 Apr 4;8(1):5608
pubmed: 29618752
J Cancer. 2019 May 14;10(9):2109-2127
pubmed: 31205572
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
BMC Med Genomics. 2021 Jan 6;14(1):6
pubmed: 33407459
Nature. 2014 Jul 17;511(7509):362-5
pubmed: 24896180
Biomolecules. 2021 Jul 20;11(7):
pubmed: 34356684
PLoS Genet. 2017 Mar 24;13(3):e1006691
pubmed: 28339459
Oncogene. 2006 Feb 23;25(8):1186-94
pubmed: 16205630
Pathogenetics. 2008 Nov 03;1(1):4
pubmed: 19014668
EMBO Rep. 2004 Oct;5(10):989-93
pubmed: 15359272
J Clin Oncol. 2015 Oct 1;33(28):3124-9
pubmed: 25940717
Bioinformatics. 2014 Oct;30(19):2813-5
pubmed: 24907369
BMC Genomics. 2018 Apr 19;19(1):270
pubmed: 29673323

Auteurs

Inès Debbabi (I)

Department of Genetics, Institut Curie, Paris, France.

Sophie Vacher (S)

Department of Genetics, Institut Curie, Paris, France.
PSL Research University, Paris, France.

Cindy Neuzillet (C)

Department of Medical Oncology, Curie Institute, Versailles Saint Quentin University, Paris, France.

Jérome Cros (J)

INSERM UMR1149, Beaujon University Hospital, Paris University, Paris, France.
Department of Pathology, Beaujon University, Hospital Paris 7 Diderot University, Paris, France.

Françoise Revillon (F)

Unit of Human Molecular Oncology, Centre Oscar Lambret, Lille, France.

Ambre Petitalot (A)

Department of Genetics, Institut Curie, Paris, France.
PSL Research University, Paris, France.

Anthony Turpin (A)

ULR9020-UMR-S 1277 Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, France.
Medical Oncology Department, CHU Lille, University of Lille, France.

Samantha Antonio (S)

Department of Genetics, Institut Curie, Paris, France.
PSL Research University, Paris, France.

Elodie Girard (E)

INSERM UMR1149, Institut Curie, Paris, France.

Célia Dupain (C)

Department of Drug Development and Innovation, Institut Curie, PSL Research University, Paris.

Maud Kamal (M)

Department of Drug Development and Innovation, Institut Curie, PSL Research University, Paris.

Pascal Hammel (P)

Department of Digestive and Medical Oncology, Paris-Saclay University, Hôpital Paul Brousse, Villejuif, France.

Ivan Bièche (I)

Department of Genetics, Institut Curie, Paris, France.
Université de Paris, Paris, France.

Julien Masliah-Planchon (J)

Department of Genetics, Institut Curie, Paris, France.
PSL Research University, Paris, France.

Sandrine M Caputo (SM)

Department of Genetics, Institut Curie, Paris, France.
PSL Research University, 75005 Paris, France.

Classifications MeSH